Conflicts of interest
Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting
Version of Record online: 1 APR 2014
© 2014 Wiley Publishing Asia Pty Ltd
Early Intervention in Psychiatry
Volume 10, Issue 1, pages 54–62, February 2016
How to Cite
Chiliza, B., Ojagbemi, A., Esan, O., Asmal, L., Oosthuizen, P., Kidd, M., Gureje, O. and Emsley, R. (2016), Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting. Early Intervention in Psychiatry, 10: 54–62. doi: 10.1111/eip.12141
Professor Piet Oosthuizen has received honoraria from Pfizer, Lundbeck, Astra-Zeneca and Cipla for speaking at educational meetings. Dr Bonginkosi Chiliza has received honoraria from Sandoz and Janssen for speaking at educational meetings. Professor Robin Emsley has received honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, Lilly, Lundbeck, Organon, Pfizer, Servier, Otsuka and Wyeth for participating in advisory boards and speaking at educational meetings, and has received research funding from Janssen, Lundbeck and AstraZeneca.
Lundbeck was not involved in any aspect of the conceptualization, design, conductance, analysis and reporting of the study.
- Issue online: 10 JAN 2016
- Version of Record online: 1 APR 2014
- Manuscript Accepted: 28 FEB 2014
- Manuscript Received: 4 SEP 2013
- Department of Science and Technology of South Africa
- Medical Research Council of South Africa
- Lundbeck International
- developing country;
- psychotic disorder;
To assess the feasibility and effectiveness of depot antipsychotic (flupenthixol decanoate) combined with an assertive monitoring programme (AMP) in first-episode schizophrenia.
This was a prospective, non-comparative, longitudinal study conducted over 12 months assessing patient acceptance, adherence, outcome in domains of psychopathology, functionality and quality of life, and tolerability.
Of 207 participants, 149 (72%) completed 12 months of treatment. Acceptance of and adherence to depot was good. Treatment response was achieved by 170 (82%) participants and remission by 124 (60%). Thirty-three (19%) responders relapsed and 10 (5%) participants met a priori criteria for treatment resistance. Treatment was generally well tolerated.
Combination of depot antipsychotic with an AMP may be an effective and safe intervention in early phases of schizophrenia, and may be particularly suitable for resource-constrained settings.